Aug 8 (Reuters) - Eli Lilly (NYSE:LLY) Canada Inc:
* ELI LILLY CANADA INC - VERZENIO (ABEMACICLIB) AVAILABLE IN CANADA FOR METASTATIC BREAST CANCER
* ELI LILLY CANADA INC - VERZENIO IS AVAILABLE IN FOUR TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)
* ELI LILLY CANADA INC - APPROVAL OF VERZENIO IS BASED ON EFFICACY AND SAFETY DEMONSTRATED IN PIVOTAL MONARCH 3, MONARCH 2 AND MONARCH 1 CLINICAL TRIALS